Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope

Long synthetic peptides and CpG-containing oligodeoxynucleotides are promising components for cancer vaccines. In this phase I trial, 19 patients received a mean of 8 (range 1–12) monthly vaccines s.c. composed of the long synthetic NY-ESO-1(79–108) peptide and CpG-B (PF-3512676), emulsified in Mont...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Baumgaertner, P., Costa Nunes, C., Cachot, A., Maby-El Hajjami, H., Cagnon, L., Braun, M., Derré, L., Rivals, J.-P., Rimoldi, D., Gnjatic, S., Abed Maillard, S., Marcos Mondéjar, P., Protti, M. P., Romano, E., Michielin, O., Romero, P., Speiser, D. E., Jandus, C.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087303/
https://ncbi.nlm.nih.gov/pubmed/27853637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1216290
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados